OpGen (OTCPK:OPGN) - Prezzo delle azioni, notizie e analisi

OPGN Panoramica delle azioni

OpGen, Inc. è un'azienda di medicina di precisione che sviluppa e commercializza soluzioni di microbiologia molecolare per le malattie infettive a rischio di vita negli Stati Uniti e a livello internazionale. Maggiori dettagli

OPGN analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Analisi del rischio

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Ha meno di 1 anno di pista di cassa

Gli utili sono diminuiti del 6.5% all'anno negli ultimi 5 anni

Prezzo delle azioni volatile negli ultimi 3 mesi

+ 2 più rischi

OpGen, Inc. Concorrenti

Cyclo Therapeutics

NasdaqCM:CYTH

US$20.1m

Zeo ScientifiX

OTCPK:ZEOX

US$20.4m

Vascular Biogenics

NasdaqCM:VBLT

US$12.1m

Pieris Pharmaceuticals

NasdaqCM:PIRS

US$21.1m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per OpGen
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$1.50
Massimo di 52 settimane	US$9.90
Minimo di 52 settimane	US$1.40
Beta	-0.60
1Variazione di 1 mese	-18.48%
Variazione a 3 mesi	-21.05%
Variazione di 1 anno	-67.03%
3Variazione a 3 anni	-99.53%
Variazione a 5 anni	-99.38%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

OpGen to raise $3.38M in direct stock offering

Sep 30

OpGen's subsidiary signs R&D agreement with FIND

Sep 20

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Aug 31

OpGen subsidiary Curetis and Annar ink Unyvero distribution partnership for Colombia

Jan 05

OpGen launches $10M private placement

Nov 24

OpGen EPS misses by $0.04, beats on revenue

Nov 11

OpGen's subsidiary and collaborators secures German funding to develop such a molecular diagnostics platform

Oct 28

Rendimenti per gli azionisti

	OPGN	US Biotechs	US Mercato
7D	-22.9%	2.4%	2.2%
1Y	-67.0%	16.2%	31.7%

Ritorno vs Industria: OPGN ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 16.2 % nell'ultimo anno.

Rendimento vs Mercato: OPGN ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.7 % nell'ultimo anno.

Volatilità dei prezzi

Is OPGN's price volatile compared to industry and market?
OPGN volatility
OPGN Average Weekly Movement	15.3%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di OPGN è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 15% ) di OPGN è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2001	93	John Tan	www.opgen.com

OpGen, Inc. è una società di medicina di precisione che sviluppa e commercializza soluzioni di microbiologia molecolare per le malattie infettive a rischio di vita negli Stati Uniti e a livello internazionale. I prodotti dell'azienda includono le cartucce applicative Unyvero, i sistemi Unyvero, i prodotti per il test Acuitas AMR Gene Panel e i kit per il test SARS CoV-2. Offre servizi di laboratorio, servizi di collaborazione, compresi accordi di software finanziato, e servizi di accordi di licenza.

OpGen, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di OpGen con la sua capitalizzazione di mercato?
OPGN statistiche fondamentali
Capitalizzazione di mercato	US$15.12m
Guadagni(TTM)	-US$9.92m
Ricavi(TTM)	US$1.27m

9.9x

Rapporto P/S

-1.3x

Rapporto P/E

OPGN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
OPGN Conto economico (TTM)
Ricavi	US$1.27m
Costo del fatturato	US$5.94m
Profitto lordo	-US$4.68m
Altre spese	US$5.24m
Guadagni	-US$9.92m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.19
Margine lordo	-369.55%
Margine di profitto netto	-783.50%
Rapporto debito/patrimonio netto	0%

Come si è comportato OPGN nel lungo periodo?

Vedi performance storica e confronto

OPGN Panoramica delle azioni

Analisi del rischio

OpGen, Inc. Concorrenti

NasdaqCM:CYTH

US$20.1m

OTCPK:ZEOX

US$20.4m

NasdaqCM:VBLT

US$12.1m

NasdaqCM:PIRS

US$21.1m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Recent updates

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives a Letter from the Nasdaq Hearings Panel Determines to Deny its Request for Continued Listing on Nasdaq

OpGen, Inc.(OTCPK:OPGN) dropped from S&P TMI Index

OpGen, Inc.(OTCPK:OPGN) dropped from NASDAQ Composite Index

OpGen, Inc. announced delayed 10-Q filing

OpGen Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on Nasdaq

Nasdaq Hearings Panel Grants Extension to OpGen, to Regain Compliance by July 8, 2024

OpGen Receives Notice from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5250(c)(1) Due to Not Filing its Quarterly Report on Form 10-Q for the Period Ended March 31, 2024

OpGen, Inc. announced delayed 10-Q filing

OpGen, Inc. Announces 1-For-10 Reverse Stock Split to Regain Compliance with the Nasdaq Capital Market’s Minimum Bid Price Listing Requirement of $1.00 Per Share

OpGen Receives Nasdaq Notice Regarding Delayed Form 10-K

OpGen, Inc. announced delayed annual 10-K filing

OpGen, Inc. announced delayed annual 10-K filing

Opgen, Inc. Announces Executive Changes

New major risk - Share price stability

New major risk - Revenue and earnings growth

OpGen Submits A Request for A Hearing Before the Panel, Which Request Stayed Any Suspension or Delisting Action by Nasdaq At Least Until the Hearing Process Concludes and Any Extension Granted by the Panel Expires

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. announced that it expects to receive $1 million in funding

OpGen, Inc. announced that it expects to receive $1 million in funding

New major risk - Share price stability

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

OpGen, Inc. to Report Q2, 2023 Results on Aug 10, 2023

OpGen Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

First quarter 2023 earnings released: US$1.25 loss per share (vs US$2.93 loss in 1Q 2022)

OpGen, Inc. to Report Q1, 2023 Results on May 15, 2023

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Full year 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

OpGen, Inc. Announces Preliminary Unaudited Revenue for 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $7.5 million.

OpGen, Inc Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Reports Goodwill Impairment Charge for the Third Quarter Ended September 30, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. to Report Q3, 2022 Results on Nov 10, 2022

OpGen, Inc. has completed a Follow-on Equity Offering in the amount of $3.38 million.

OpGen, Inc. Announces Successful Completion of Clinical Trial Enrollment for Unyvero Urinary Tract Infection Panel

OpGen to raise $3.38M in direct stock offering

OpGen's subsidiary signs R&D agreement with FIND

Nasdaq Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

Opgen, Inc. Launches Ares Sequencing Services in the U.S. from Its Rockville, Maryland Laboratory

OpGen launches sequencing services for infectious diseases in US

OpGen, Inc. Provides Revenue Guidance for Fiscal Year 2022

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

OpGen, Inc. to Report Q2, 2022 Results on Aug 11, 2022

OpGen reports preliminary revenue estimate for Q2 2022

OpGen, Inc. Announces Publication of Results of Unyvero Hospitalized Pneumonia (Hpn) Panel for Detection of Bacterial Respiratory Tract Pathogens from Serial Specimens Collected from Hospitalized Covid-19 Patients

OpGen, Inc. Announces Publication of Results from Major Clinical Study Using Unyvero Hospitalized Pneumonia Panel in the Lancet Respiratory Medicine

OpGen, Inc. Provides Earnings Guidance for the Year 2022

OpGen, Inc., Annual General Meeting, Jun 09, 2022

OpGen, Inc. Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

OpGen, Inc. Provides Revenue Guidance for the Year 2022

OpGen, Inc. Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

OpGen gains on insider buying

OpGen, Inc. Submits Updated 510(k) Summary to FDA For Acuitas AMR Gene Panel for Isolates

OpGen submits 510(k) summary to FDA for Acuitas AMR Gene Panel for Isolates

OpGen, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Evan Jones, Director of Opgen, Inc. Will Not Stand for Re-Election at the 2021 Annual Meeting of Stockholders

OpGen, Inc., Annual General Meeting, Jun 09, 2021